scorecardresearch
Tuesday, November 5, 2024
TopicBharat Biotech

Topic: Bharat Biotech

Covid vaccine patents can be waived without hurting firms like Bharat Biotech. Here’s how

It is time countries acted with a humanitarian approach at WTO and relaxed IPR provisions for Covid-19 vaccines. And it can be done without disincentivising R&D efforts.

9 states tell SC they’re unlikely to get enough Covid vaccines stock for 18+ group by May-end

In affidavits to SC, 9 states have said SII & Bharat Biotech have either expressed inability to supply the stock by May-end or said there will be staggered delivery over the next 2-3 months.

Disheartening to see some states complaining about Covaxin supply intentions — Bharat Biotech

In a tweet Wednesday, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on 10 May.

Bharat Biotech refuses to supply Covaxin to Delhi citing govt directives, alleges Sisodia

Delhi Deputy CM Manish Sisodia said Covaxin manufacturer in a letter referred to instructions from govt officials and it means that central govt is controlling the vaccine supply.

Modi govt expert panel recommends Covaxin for phase 2/3 clinical trials on 2-18-yr-olds

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, is being used on adults in India's ongoing Covid vaccination drive.

Still playing the book-vaccine-slot game on CoWin? That’s because there’s a shortage of doses

Modi govt Friday said it had told states to prioritise second dose of Covid vaccines over first dose in a 70:30 ratio, in what may be its first admission about shortage of vaccines.

Bharat Biotech reduces Covaxin price for state govts to Rs 400 per dose

The move to cut the price from Rs 600 per dose follows widespread criticism of Bharat Biotech's pricing policy as it sold Covaxin to the central government at Rs 150 per dose.

Modi govt asks Serum Institute, Bharat Biotech to lower prices of Covid vaccines

The move comes after many states objected to different pricing of the vaccines, with Delhi CM Arvind Kejriwal saying this is not time for profiteering.

Bharat Biotech scales up Covaxin manufacturing capacity to 700 million doses a year

The company had 200 million doses capacity when it started producing Covaxin in the beginning, say sources.

Modi govt approves Rs 4,500-cr advance payment to help vaccine makers ramp up production

SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.

On Camera

Trudeau is nursing snakes in his own backyard. Misguided Sikhs in Canada are losing the plot

By turning a blind eye to the snakes in his own backyard, Trudeau is setting the stage for a disaster of epic proportions for his country, his people, and the world at large.

Watch CutTheClutter: Flattening INR-USD rate, and debate on pros and cons of a ‘strong’ rupee

In Episode 1544 of CutTheClutter, Editor-in-Chief Shekhar Gupta looks at some top economists pointing to the pitfalls of ‘currency nationalism’ with data from 1991 to 2004.

India carries out 1st patrol in Depsang since disengagement with China, to take things ‘slow’

While there are patrolling points (PP) 10, 11, 12, 12A and 13 in the Depsang Plains, the patrol in the region Monday was carried out to only one point as decided by India and China.

Xi wanted to teach India about imbalance of power. We should take a budgetary lesson from it

While we talk much about our military, we don’t put our national wallet where our mouth is. Nobody is saying we should double our defence spending, but current declining trend must be reversed.